Werner syndrome cells are sensitive to DNA cross-linking drugs.

The FASEB journal : official publication of the Federation of American Societies for Experimental Biology

Volumn 15, Issue 7, 2001, Pages 1224-1226

  Poot, M ^a   Yom, J S ^a   Whang, S H ^a   Kato, J T ^a   Gollahon, K A ^a   Rabinovitch, P S ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CROSS LINKING REAGENT; DNA; ENZYME INHIBITOR; HELICASE; INTERCALATING AGENT; RECQ HELICASE; WRN PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL LINE; DRUG EFFECT; GENETICS; HUMAN; LYMPHOCYTE; METABOLISM; PATHOLOGY; PHYSIOLOGY; WERNER SYNDROME;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE; CROSS-LINKING REAGENTS; DNA; DNA HELICASES; ENZYME INHIBITORS; HUMANS; INTERCALATING AGENTS; LYMPHOCYTES; RECQ HELICASES; WERNER SYNDROME;

MLCS; MLOWN;

EID: 0035349905     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.00-0611fje     Document Type: Article

References (0)